Member Info for Saintsmith

https://apple.news/AFad_MFaqQsCHL41xxUN11Q

Tell these Shanghai citizens that a LFT with 15 minUte results isn’t a game changer .

Shanghai citizens waiting 72 hours for negative test results to enter public places .

https://apple.news/AsMvhOj_iSHSIGhEJ18a01A

Good find ted . Good to see a presence on the media .
Let’s hope more of the mainstream media pick up on the story .
Novacyt were definitely excited yesterday and know we know why .

Neil Oliver is fantastic .

Pandemic preparedness for the coming winter .
Hopefully the LFT have a decent expiry date .

Home use 15 minute LFT saliva test .
It’s a game changer .
We have been waiting for this .
If this would have been approved last year the SP would still be in double figures .
I know more people than ever with covid now.

The expensive government PCR lab testing has gone now .
This could well be the future for forward thinking world governments in preparation for winter and the next variant of concern .

I had a feeling their would be an RNS out today .
There was a lot of excititement and positive communication from Novacyt yesterday .

Nudge , nudge , wink , wink .

We have an assay for camelpox testing . I wonder if TATA are aware .

https://main.mohfw.gov.in/sites/default/files/Guidelines%20for%20Management%20of%20Monkeypox%20Disease.pdf

From the IMCR regarding monkeypox testing .

6.3 Diagnostic modalities for Monkeypox with ICMR NIV Pune
For the confirmation of Monkeypox on the suspected clinical specimens:
a) PCR for Orthopoxvirus genus [Cowpox, Buffalopox, Camelpox, Monkeypox] will be done
b) If specimen will show positivity for the Orthopoxvirus, it would be further confirmed by
Monkeypox specific conventional PCR or real time PCR for Monkeypox DNA
c) Additionally, virus isolation and the Next Generation Sequencing of clinical samples
(Miniseq and Nextseq) will be used for characterization of the positive clinical specimens
All the clinical specimens should be transported to the Apex laboratory of ICMR-NIV Pune routed through the Integrated Disease Surveillance Programme network of the respective district/state
6.4 Contact Persons from ICMR-National Institute of Virology Pune Maharashtra, India for further queries related to collection and transportation of the clinical specimens

More monkeypox cases in the U.K. .
Novacyt your global responder skills are needed .

https://apple.news/A6SD0sCz6R4-PXN3FiIsrDw

I think the WHO are just trying to stay relevant K.

It does seem very strange that these scare stories regarding youngsters is also while the WHO are advocating/pushing for ages 5-11 to be vaccinated .
Dont you think ?

Does this mean our LFT antibody test is no longer research use only ?

https://novacyt.com/wp-content/uploads/2022/05/PathFlow%C2%AE-SARS-CoV-2-IgG-Rapid-Test-Flier-R3-GMM166-RGB-SCREEN.pdf

Sngyf up 24% in the US ?

Invest in a portfolio of at least five at-home testing technologies that will empower Americans, improve equitable access, and mitigate the impacts of future pandemics.

Support advanced development and approval of pathogen-agnostic, pathogen-specific, and host-directed diagnostics across the spectrum of potential threats, including:
– Evaluating laboratory and point-of-care testing that leverages existing platforms and can be rapidly adapted to emerging threats,
– Accelerating emerging technologies that move testing closer to the patient and facilitate testing in limited healthcare resource settings, and
– Achieving regulatory clearance of one test on at least two separate home use molecular diagnostic testing platforms.

BARDA COVID-19 Therapeutic Investments
Addressing the COVID-19 pandemic requires developing and procuring therapeutics for individuals across the continuum of disease, from mild infections to the severely ill. BARDA invested COVID-19 sup- plemental funds to accelerate the clinical development and manufacturing scale-up of therapeutic candi- dates most likely to have a broad public health impact. BARDA supported screening existing monoclonal antibodies and small molecule compounds with existing clinical or preclinical data for activity against SARS-CoV-2. An existing partnership was expanded by BARDA to develop new targeted monoclonal anti- bodies using a proven technology that was licensed for another indication. In addition, BARDA supported the collection, distribution, and EUA of COVID-19 convalescent plasma, which was used to treat approx- imately 400,000 patients.

BARDA COVID-19 Diagnostic Investments
Diagnostics are a crucial tool to aid in the diagnosis and inform management and treatment of COVID-19 patients, which can assist in reducing the spread of this deadly disease. BARDA supported multiple as- says for SARS-CoV-2 infection that spanned over 40 diagnostic products. From May to June 2020, ap- proximately 40% of the COVID-19 diagnostics available for Americans were the result of BARDA invest- ments. These included high-throughput devices in commercial clinical labs and hospitals, point-of-care tests for use in provider offices and limited testing resource settings (such as nursing homes), and over- the-counter tests for home use. Tests supported also included multiplex molecular diagnostic tests that detect SARS-CoV-2, in addition to influenza A and B viruses, and, in some cases, respiratory syncytial virus (RSV). BARDA’s first supported diagnostic was authorized for emergency use in March 2020. BAR- DA also supported the development of diagnostics to distinguish specific SARS-CoV-2 variants when needed to inform therapeutic usage. BARDA also collaborated with NIH, providing both financial support and subject-matter expertise to facilitate rapid launch of the RAD-X program.
In parallel, BARDA invested in rapidly deployable capabilities that augment current diagnostic technol- ogies, leveraging the physiological, host biomarkers, and vital sign data from patients. These included exploring the capability of non-invasive, wearable physiological sensors, remote monitors, and telemedi- cine tools to empower individuals and health care providers to better inform on infection status (including those that may be asymptomatic or pre-symptomatic) or infection severity. Such technologies could aid in identifying at-risk individuals, reducing further transmission by providing early indication of infection and monitoring mildly ill patients that may be progressing to more severe illness.
In addition, BARDA supported technologies that included electronic health records – integrated algo- rithms, apps, and blood biomarker-based in vitro diagnostics. These efforts empowered health care pro-
viders in the emergency department and hospital. Such technologies could provide early information on health deterioration to aid health care providers in management of patients to improve patient outcomes and allocate resources.
BARDA also partnered with DoD to make substantial investments in domestic diagnostics manufactur- ing, which will increase diagnostic test production capacity output from 18 million to 72 million tests per month in 2022 and will help ensure domestic supply.
BARDA’s COVID-19 response continues with new countermeasures in development, and BARDA antici- pates incorporating current and future activities to address SARS CoV-2 as a durable facet of its mission. In addition, there is an opportunity to expand indications beyond COVID-19 .